The question „will the public payer reimburse this?” is asked in Poland every day, and almost always in the wrong form. No authority issues individual reimbursement decisions on guaranteed benefits. What exists instead are three normative layers and two narrow individual routes — and between them a gap in which the cancer patient pays for items of entirely different legal status.

A study by the Healthcare Poland Foundation. The analysis follows an anonymised case of locally advanced squamous cell carcinoma of the head and neck (cT4 N2, PD-L1 CPS positive) in a patient holding a Polish oncological diagnosis and treatment card (DiLO) who began systemic treatment abroad, in a country outside the EU and the EEA.

1. Who actually decides on financing

Asking about „the payer’s decision” presumes an authority adjudicating an individual patient’s right to a specific technology. For guaranteed benefits, no such authority exists in the Polish system. The scope of financing follows from three normative layers, each operating independently, each capable of closing the route on its own.

The first layer is the benefit basket — the ministerial regulations on guaranteed benefits in hospital care, outpatient specialist care, rehabilitation and dentistry. The second is the reimbursement list — the Minister of Health’s announcement, including drug programmes. The third is clinical qualification: the provider establishes that the patient meets the criteria set by the first two layers. The National Health Fund does not assess the patient — it settles accounts with the provider.

The practical consequence is often an expensive one: an „application to the Fund for reimbursement of a medicine” does not exist as a legal institution. Letters of that kind land in a competence vacuum; the addressee is always the healthcare provider that would administer and account for the drug.

2. The treatment plan, element by element

The table below answers two questions at once. The „status” column states whether an element is publicly financed when delivered in Poland. The final column states what follows when the same element is delivered abroad. Separating the two questions is the precondition of an honest account — conflating them produces the belief that the system does not finance the treatment, when in fact it does not finance the location.

The table covers elements of radical treatment only. Statuses reflect the legal position as at 13 September 2026.

Two distinctions that settle the matter

The first concerns the status of the drug. Pembrolizumab in the perioperative setting is not an off-label use: on 29 October 2025 the European Commission authorised this regimen for resectable locally advanced squamous cell carcinoma of the head and neck expressing PD-L1 (CPS ≥ 1), as two neoadjuvant cycles followed by an adjuvant phase with radiotherapy and up to fifteen further cycles. The drug is therefore authorised and unreimbursed — a legally different situation from off-label use. What is off-label is the addition of induction chemotherapy to the neoadjuvant phase. In correspondence with providers and with funding organisations, this distinction determines whether a request is taken seriously at all.

The second concerns the supply category. A medicine restricted to hospital use is not obtainable in a community pharmacy. „The patient’s own drug” means, in practice, a purchase made by a private healthcare institution which administers the drug and invoices it together with the administration — which is why private valuations exceed the catalogue price of the vial.

3. Accounting for the gap: how much is systemic, how much is location

In the modelled variant of full treatment abroad, the upper valuation comes to some PLN 1.74 million. That figure contains two categories of cost of entirely different nature, and separating them is a duty of elementary integrity — particularly towards the donors of the public fundraisers that such situations generate.

The systemic gap is the part the public payer will not finance anywhere — neither in Warsaw nor in Tel Aviv. In this case it consists solely of pembrolizumab. At a catalogue price of roughly PLN 20,100 per 100 mg vial, a 200 mg dose costs about PLN 40,300; two neoadjuvant cycles come to some PLN 80,500 and fifteen adjuvant cycles to some PLN 604,000 — together about PLN 684,000 for the drug alone, or PLN 720,000–750,000 with commercial administration at home.

The cost of location is the part that is free in Poland and becomes payable only because the benefit was delivered elsewhere: surgery with reconstruction and the perioperative reserve, chemoradiotherapy, staging, follow-up imaging, travel and accommodation. In the model this is about PLN 640,000. The remaining PLN 380,000 covers reserves, the currency margin, rehabilitation and prosthetics — of which rehabilitation and conventional prosthetics are guaranteed, while implant-supported restoration is guaranteed to no one.

4. The two individual routes and the limits of each

The system knows exactly two individual routes, and both are narrow.

Emergency access to drug technologies. The application is filed by the provider, following a favourable opinion from a national or regional consultant. The medicine must hold a marketing authorisation, must be unreimbursed in the given indication and necessary to save life or health, and the publicly financed technologies available must have been exhausted. That last condition carries a chronological consequence rarely stated openly: in the perioperative setting it can be satisfied only after surgery and chemoradiotherapy, never before. Funding is granted for three months or three cycles, renewable, and the budget remains capped at hospital level — so even a favourable consultant’s opinion is no guarantee. The route closes automatically if a negative recommendation or a refusal of reimbursement has been issued in that indication; in the indication analysed here neither has occurred, which works in the applicant’s favour.

Consent to treatment outside the country. The President of the Fund may refer a patient for a benefit that is not performed domestically. Consent is prior only, does not cover costs already incurred, and does not extend to a technology that is not a guaranteed benefit. In a case such as this one the conditions fail twice over: reconstructive surgery and chemoradiotherapy are performed in Poland, and the drug is not a guaranteed benefit. An application retains documentary value alone — as evidence in the debate on the shelf life of knowledge in the basket, not as a financing route.

A third possibility is worth remembering but not assuming: a manufacturer’s early access programme covering the interval between authorisation and reimbursement. The absence of such a programme is itself material for systemic analysis.

5. A DiLO card without a place on the waiting list

The oncological diagnosis and treatment card confers three things: the right to treatment without a referral, the removal of volume caps on benefits within the pathway, and a separate waiting list with statutory timelines. It confers nothing, however, until the treating provider accepts the card and enters the patient on the list. Until that moment the card is a document, not a process.

The consequence is easy to overlook and expensive. Until entry is made, no statutory deadline runs, no care coordinator is assigned to the case, there is no attending physician, no tumour board and no treatment plan. The patient’s entire legal position in the pathway — the deadline for establishing a plan, the right to a justification of the date offered, the right to a certificate of entry — hangs on a single act of registration.

Beginning treatment abroad does not, of itself, impair the rights attached to the card; the National Oncology Network Act imposes no such condition. A plan subsequently established by the tumour board is a continuation plan, and the team is not bound by it — it may adopt, modify or reject the regimen, and that is a clinical, not an administrative, decision.

Entry on the list and physical examination are two distinct acts

The distinction matters wherever a patient is temporarily away from the place of treatment. The statute requires, for entry, a notification and a basis — a referral and the card; it does not require the patient’s presence at the registration desk, and with an electronic referral there is no obligation to deliver an original document. Nothing in the law prevents an authorised representative from completing registration, obtaining a dated entry, a certificate of entry and an appointment for examination within the next available window. Deadlines then run from the date of entry, and the physical examination becomes part of implementing the plan rather than a condition of entering the system.

Whether a given registration desk accepts this is a matter of organisational practice, not of law. A refusal is worth requesting in writing together with its stated basis — such a document serves both the appeal route and systemic analysis.

Remote examination is a separate question. The Medical Professions Act permits examination by means of ICT systems, but where the qualification concerns extensive resection with microvascular reconstruction, a refusal to treat such an examination as sufficient is clinically intelligible and is not a battleground.

6. Conclusions

• What is unreimbursed is the drug, not the treatment. Everything that is most expensive, most hazardous and most dependent on continuity — surgery with reconstruction, chemoradiotherapy, post-operative care — is guaranteed and uncapped in Poland. The opposite message, widely repeated in public debate, is false and corrodes trust in the system.
• A public fundraiser finances two different things and should name them separately. One part covers the systemic gap, the other a decision about location. Both are legitimate; merging them into a single figure is not.
• A DiLO card without entry on the waiting list starts no clock. The constitutive act is registration with the treating provider, and it may be performed by an authorised representative.
• The adjuvant phase is the only part of the gap that can still be shifted back onto the system — solely through emergency access to drug technologies, solely on the provider’s application and solely after local treatment. The precondition is that local treatment takes place at home.
• The distance between authorisation and reimbursement is the measure of the shelf life of knowledge in the basket. A regimen authorised across the European Union in October 2025 remains outside the list more than a year later — and it is that distance, rather than any single application, that is the proper subject of public debate.